BGOG-ov84/TroFuse-022

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer

Open
Trial drug
Sacituzumab tirumotecan
Grade
High grade, Low grade, Other / unknown
Prior lines
1
Histology
Serous, Endometrioid Clear-cell Carcinocarcoma
Platin
Platinum sensitive
Phase
III

Treatment

The treatment option in this study is Sacituzumab Tirumotecan maintenance treatment with or without bevacizumab versus standard of care .
Sacituzumab Tirumotecan is given intravenously.

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.